Ari M Melnick
Overview
Explore the profile of Ari M Melnick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
6417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen V, Namba H, Porter H, Shlyueva D, Lopez E, Melcher A, et al.
Blood
. 2025 Feb;
PMID: 40009485
Despite the approval of several new treatments for patients with B-cell lymphoma, there is still a large unmet need. Diffuse large B-cell lymphoma (DLBCL) and Follicular lymphoma (FLs) are the...
2.
Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al.
Cancer Cell
. 2025 Feb;
43(3):537-551.e7.
PMID: 39983725
Tumor resistance to chimeric antigen receptor T cell (CAR-T) and, in general, to adoptive cell immunotherapies (ACTs) is a major challenge in the clinic. We hypothesized that inhibiting the tumor...
3.
Flowers C, Anantha R, Leautaud V, Desai P, Donald C, Hildebrandt M, et al.
Blood Cancer Discov
. 2025 Feb;
6(2):79-93.
PMID: 39898759
This review underscores our shared responsibility to champion multidimensional strategies rooted in basic and translational science, community involvement, and societal responsiveness for a meaningful impact. Unifying themes include the need...
4.
Kim J, Schanzer N, Singh R, Zaman M, Garcia-Medina J, Proszynski J, et al.
Int Rev Cell Mol Biol
. 2025 Jan;
390():67-108.
PMID: 39864897
Acute myeloid leukemia (AML) is a complex cancer, yet advances in recent years from integrated genomics methods have helped improve diagnosis, treatment, and means of patient stratification. A recent example...
5.
Gao V, Yang R, Das A, Luo R, Luo H, McNally D, et al.
Nat Commun
. 2025 Jan;
16(1):684.
PMID: 39814735
No abstract available.
6.
Barton B, Son F, Verma A, Bal S, Tang Q, Wang R, et al.
Nat Immunol
. 2025 Jan;
26(2):200-214.
PMID: 39789376
Hematopoietic stem cells must mitigate myriad stressors throughout their lifetime to ensure normal blood cell generation. Here, we uncover unfolded protein response stress sensor inositol-requiring enzyme-1α (IRE1α) signaling in hematopoietic...
7.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, et al.
Cancer Cell
. 2024 Dec;
43(1):49-68.e9.
PMID: 39642889
T cell-based immunotherapies have demonstrated effectiveness in treating diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) but predicting response and understanding resistance remains a challenge. To address this,...
8.
Xu C, Us I, Cohen-Setton J, Milo M, Sidders B, Fitzgibbon J, et al.
bioRxiv
. 2024 Nov;
PMID: 39574568
Combination therapies offer promise for improving cancer treatment efficacy and preventing recurrence. However, identifying optimal drug combinations tailored to specific cancer subtypes and individual patients is extremely challenging due to...
9.
Gao V, Yang R, Das A, Luo R, Luo H, McNally D, et al.
Nat Commun
. 2024 Nov;
15(1):9432.
PMID: 39487131
Identifying cell-type-specific 3D chromatin interactions between regulatory elements can help decipher gene regulation and interpret disease-associated non-coding variants. However, achieving this resolution with current 3D genomics technologies is often infeasible...
10.
Portelinha A, Wang S, Parsa S, Jiang M, Gorelick A, Mohanty S, et al.
J Exp Med
. 2024 Sep;
221(10).
PMID: 39235528
The translocation t(14;18) activates BCL2 and is considered the initiating genetic lesion in most follicular lymphomas (FL). Surprisingly, FL patients fail to respond to the BCL2 inhibitor, Venetoclax. We show...